Shire Licenses Parion’s P-321 for Dry Eye Disease

May 12, 2017: By Joan McKenna

ShireShire has signed an exclusive global licensing agreement to develop and commercialize Parion Sciences’ P-321 for dry eye disease in adults, the two companies announced May 1.

P-321 is an epithelial sodium channel (ENaC) inhibitor in Phase II development as a topical treatment to address tear volume deficiency and promote ocular surface healing.

Shire will make an initial $20 million up-front payment, plus a potential near-term milestone payment of $20 million, to lead development of P-321.

Parion is entitled to additional milestone payments, and the deal has a potential total value of $535 million.

Parion, of Durham, NC, has the option to co-fund development through later stages in exchange for royalties. In addition, Parion has the option to co-fund and benefit from commercialization.

Shire, headquartered in Dublin, launched Xiidra for dry eye disease—its first ophthalmic product—in August 2016.

 

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Launches Stellaris Elite for Retinal Surgery in US

Sentencing Delayed for Florida Retina Specialist Melgen

Valeant Receives FDA Complete Response Letter for Vyzulta

US FDA Clears Optovue Software for Corneal Epithelial Thickness Mapping

Ocular Therapeutix Names Daniel Bollag as Regulatory Chief

Eylea Sales Continue to Increase; Lucentis Gains New Indications

RXi Pharmaceuticals Signs Common Stock Purchase Agreement for Up to $15 Million

Allegro’s Luminate Posts Positive Results in Phase IIb Stage 2 Trial for Diabetic Macular Edema

Omeros’ Omidria Revenues Grow 71 Percent

AGTC Receives US FDA Orphan Drug Designation for Gene Therapy to Treat X-Linked Retinitis Pigmentosa

Aerpio Shares Begin Trading on OTCQB Market

Aerie Reports FDA Concerns over Contract Manufacturer’s Plant

Valeant’s Bausch + Lomb Revenues Dip 3 percent in Q2-2017

Ocular Therapeutix Reports $66 Million in Cash, Cash Equivalents

Imprimis’ Q2-2017 Ophthalmology Revenues Increase 70 percent

Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

Johnson & Johnson Vision to Acquire TearScience

Mynosys Receives $1 Million Grant from NEI to Commercialize Zepto

Ocular Therapeutix Eliminates 26 Positions; New CEO Takes Helm

Inotek Stops Development of Trabodenoson after Second Failed Study

Coming soon

2017 Glaucoma Pharmaceuticals Report: A Global Market Analysis for 2016 to 2022